Literature DB >> 16356826

Molecular chaperones throughout the life cycle of the androgen receptor.

Jennifer Prescott1, Gerhard A Coetzee.   

Abstract

Aberrant signaling by the androgen receptor contributes to the initiation and progression of prostate cancer. The involvement of molecular chaperones in the processes of folding, activation, trafficking, and transcriptional activity of the androgen receptor provide different points along the signaling axis where regulation of androgen receptor activity can be hijacked to provide growth signals for clonal selection in cancer progression. Evidence exists of abnormal chaperone expression that could contribute to the upregulation of AR activity in prostate tumors. Regardless of whether chaperones are involved in the causation of prostate carcinogenesis, molecular chaperones provide therapeutic targets for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16356826     DOI: 10.1016/j.canlet.2004.12.037

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  35 in total

1.  Proteomic analysis of the androgen receptor via MS-compatible purification of biotinylated protein on streptavidin resin.

Authors:  Ryan J Austin; Heidi M Smidansky; Carly A Holstein; Deborah K Chang; Angela Epp; Neil C Josephson; Daniel B Martin
Journal:  Proteomics       Date:  2011-12-12       Impact factor: 3.984

2.  Activation of the DNA-dependent protein kinase stimulates nuclear export of the androgen receptor in vitro.

Authors:  Leonard C Shank; Joshua B Kelley; Daniel Gioeli; Chun-Song Yang; Adam Spencer; Lizabeth A Allison; Bryce M Paschal
Journal:  J Biol Chem       Date:  2008-02-12       Impact factor: 5.157

3.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

Review 4.  Role of androgen receptor splice variants, their clinical relevance and treatment options.

Authors:  S Wach; H Taubert; M Cronauer
Journal:  World J Urol       Date:  2019-01-19       Impact factor: 4.226

5.  Molecular chaperoning by glucose-regulated protein 170 in the extracellular milieu promotes macrophage-mediated pathogen sensing and innate immunity.

Authors:  Daming Zuo; Xiaofei Yu; Chunqing Guo; Huanfa Yi; Xing Chen; Daniel H Conrad; Tai L Guo; Zhengliang Chen; Paul B Fisher; John R Subjeck; Xiang-Yang Wang
Journal:  FASEB J       Date:  2011-12-29       Impact factor: 5.191

6.  Steroid signaling activation and intracellular localization of sex steroid receptors.

Authors:  Tiziana Giraldi; Pia Giovannelli; Marzia Di Donato; Gabriella Castoria; Antimo Migliaccio; Ferdinando Auricchio
Journal:  J Cell Commun Signal       Date:  2010-11-16       Impact factor: 5.782

7.  Association study of androgen signaling pathway genes in polycystic ovary syndrome.

Authors:  Aline Ketefian; Michelle R Jones; Ronald M Krauss; Yii-Der I Chen; Richard S Legro; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2015-10-20       Impact factor: 7.329

8.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

9.  Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male.

Authors:  Guadalupe Navarro; Weiwei Xu; David A Jacobson; Barton Wicksteed; Camille Allard; Guanyi Zhang; Karel De Gendt; Sung Hoon Kim; Hongju Wu; Haitao Zhang; Guido Verhoeven; John A Katzenellenbogen; Franck Mauvais-Jarvis
Journal:  Cell Metab       Date:  2016-04-28       Impact factor: 27.287

10.  Generation and analysis of an androgen-responsive myoblast cell line indicates that androgens regulate myotube protein accretion.

Authors:  Y Chen; N K L Lee; J D Zajac; H E MacLean
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.